Benepharma SPRL
2.2 FTEThe score of Benepharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +42 % Total assets +12 % Headcount (avg FTE) +16 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Benepharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 161,674 € | ||||
| Equity | 459,080 € | ||||
| Cash | 138,435 € | ||||
| EBITDA | 317,667 € | ||||
| Total assets | 813,930 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 20 Aug 2024
- Year ended 31 Dec 2022filed on 21 Aug 2023
- Year ended 31 Dec 2021filed on 14 Jul 2022
Benepharma's financial analysis
- Solvency56.4%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Benepharma
Benepharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0685.992.809
- VAT number
- BE0685992809
- Peppol
- Registered · 0208:0685992809 · as of 09 Nov 2026
- Legal form
- SPRL
- Incorporated
- 15 Dec 2017
- Registered office
- 3090 Overijse
- Size
- Micro · 2.2 FTE
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Benepharma (SPRL) has been based in Overijse since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 161,674 € and equity of 459,080 €; its revenue is not published. With 2.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 56.4%, above the median of its sector (44.2%).
Companies similar to Benepharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Eversel Retail sale of pharmaceutical products Heusden-Zolder · balance sheet €1.02m
- Pharmacie Stassen-BYA Retail sale of pharmaceutical products Juprelle · balance sheet €1.18m
- Talpa Farma Retail sale of pharmaceutical products Anderlecht · balance sheet 547,932 €
- Herseltpharma Retail sale of pharmaceutical products Herselt · balance sheet €1.31m
- Vanlerberghe Invest Retail sale of pharmaceutical products Torhout · balance sheet €1.38m
- Global-E-Care Retail sale of pharmaceutical products Antwerp · balance sheet €1.41m
- B&B Pharma Retail sale of pharmaceutical products Beersel · balance sheet 811,436 €
- Bloos Retail sale of pharmaceutical products Anzegem · balance sheet 824,528 €
Frequently asked questions about Benepharma
What is the revenue of Benepharma?
Benepharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Benepharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0685992809 for Benepharma, if the company is VAT-registered. Its company number (CBE) is 0685.992.809.
Where is the registered office of Benepharma?
According to the CBE register, the registered office of Benepharma is in 3090 Overijse.
What is the equity of Benepharma?
At the close of the 2025 financial year, the equity of Benepharma amounts to 459,080 €, a solvency of 56.4% of total assets.
How many people work at Benepharma?
2.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Benepharma?
The register lists 1 active mandates at Benepharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Benepharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →